-+ 0.00%
-+ 0.00%
-+ 0.00%
Arcturus Expands Meiji Seika Pharma Partnership With $50 Million Equity Investment
Share
Listen to the news
Arcturus Expands Meiji Seika Pharma Partnership With $50 Million Equity Investment
  • Arcturus Therapeutics expanded its collaboration with Meiji Seika Pharma, including a $50 million equity investment at an 80% premium.
  • Meiji will purchase unregistered securities at $20.27 per share, representing 7.9% of outstanding shares following the transaction.
  • The partners signed an exclusive license agreement applying ARCT-154 technology to an undisclosed therapeutic area.
  • A memorandum of understanding outlines a potential collaboration using the Arcturus platform for pandemic preparedness and response in Japan.
  • Proceeds will accelerate ARCT-2601 development for OTC deficiency, the first mRNA therapeutic using the LUNAR 2.0 delivery platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611160830BIZWIRE_USPR_____20261116_BW054386) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending